Suppr超能文献

多种取代的二乙基(吡咯烷-2-基)膦酸酯的合成

Synthesis of Diversely Substituted Diethyl (Pyrrolidin-2-Yl)Phosphonates.

作者信息

Bagán Andrea, López-Ruiz Alba, Abás Sònia, Molins Elies, Pérez Belén, Muneta-Arrate Itziar, Callado Luis F, Escolano Carmen

机构信息

Laboratory of Medicinal Chemistry, Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Fo Sciences, University of Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain.

Institute of Biomedicine, University of Barcelona, 08028 Barcelona, Spain.

出版信息

Molecules. 2025 May 7;30(9):2078. doi: 10.3390/molecules30092078.

Abstract

Imidazoline I receptors (I-IR) are untapped therapeutic targets lacking a structural description. Although the levels of I-IR are dysregulated in a plethora of illnesses, the arsenal of ligands that can modulate I-IR is limited. In this framework, we have reported several new structural families embodying the iminophosphonate functional group that have an excellent affinity and selectivity for I-IR, and selected members have demonstrated relevant pharmacological properties in murine models of neurodegeneration and Alzheimer's disease. Starting with these iminophosphonates, we continued to exploit their high degree of functionalization through a short and efficient synthesis to access unprecedented 2,3-di, 2,2,3-tri, 2,3,4-tri, and 2,2,3,4-tetrasubstituted diethyl (pyrrolidine-2-yl) phosphonates. The stereochemistry of the new compounds was unequivocally characterized by X-ray crystallographic analyses. Two selected compounds with structural features shared with the starting products were pharmacologically evaluated, allowing us to deduce the required key structural motifs for biologically active aminophosphonate derivatives.

摘要

咪唑啉I受体(I-IR)是尚未开发的治疗靶点,目前尚无结构描述。尽管I-IR的水平在众多疾病中失调,但能够调节I-IR的配体库却很有限。在此框架下,我们报道了几个包含亚氨基膦酸酯官能团的新结构家族,它们对I-IR具有优异的亲和力和选择性,并且选定的成员在神经退行性疾病和阿尔茨海默病的小鼠模型中已显示出相关的药理特性。从这些亚氨基膦酸酯开始,我们通过简短而高效的合成方法继续利用它们的高度官能化,以获得前所未有的2,3-二取代、2,2,3-三取代、2,3,4-三取代和2,2,3,4-四取代的二乙基(吡咯烷-2-基)膦酸酯。通过X射线晶体学分析明确表征了新化合物的立体化学。对两种具有与起始产物相同结构特征的选定化合物进行了药理评估,使我们能够推断出生物活性氨基膦酸酯衍生物所需的关键结构基序。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1103/12073250/1843c4a3cc52/molecules-30-02078-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验